Sponsors (2)
The bill removes tax and benefit-eligibility barriers to joining clinical trials—encouraging participation and protecting low-income recipients—but does so at the cost of reduced tax revenue, higher program spending, and added administrative and verification burdens for officials and sponsors.
People who participate in approved clinical trials will not owe federal income tax on payments or reimbursements they receive for participation or related expenses.
Low-income and other benefit recipients who join clinical trials will keep trial payments from reducing eligibility or benefit amounts for federal programs like SNAP and Medicaid.
Prospective participants face fewer financial disincentives to enroll, likely increasing willingness to join clinical trials and potentially speeding medical research and access to experimental treatments.
Excluding clinical trial payments from taxable income and from benefit-income calculations will reduce federal tax receipts and may increase federal and state program spending, producing a net fiscal cost.
Ambiguities in the statutory definitions and the link between tax treatment and benefit eligibility could create verification challenges for benefit administrators and lead to disputes with the IRS over which payments qualify.
Sponsors, employers, and health systems may face additional administrative and compliance burdens to track, document, and report which payments meet the law's definition to ensure correct tax and benefit treatment.
Based on analysis of 2 sections of legislative text.
Excludes payments and reimbursements for participation in approved clinical trials from taxable income and from income/resource tests for federal and federally-funded state/local benefits.
Introduced June 26, 2025 by Mike Kelly · Last progress June 26, 2025
Creates a new tax rule that says money people receive for taking part in approved clinical trials—both payments for participating and reimbursements for reasonable trial-related expenses—is not taxable income. It also requires federal programs and any state or local program that gets federal funds to ignore those clinical-trial payments when calculating a person’s income or resources for benefit eligibility and benefit amounts. The change applies to amounts paid after December 31, 2025.